Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics' stock price has experienced several events and trends in the past six months. In November 2025, the company reported Q3 financial results with collaboration revenue of $13.4 million and a net loss of $27.9 million. In December 2025, Voyager reported revenues of $15.34 million, surpassing estimates, and a quarterly loss of $0.46 per share, also beating estimates. In March 2026, Voyager reported Q4 and full-year 2025 results, ending the year with a cash position of $202 million. Collaboration revenue for the full year was $40.4 million, and the net loss widened to $119.72 million. The resignation of Chief Medical Officer Toby Ferguson in February 2026 was noted. As of March 27, 2026, shares were trading at $3.96, underperforming the S&P500 Index. Technical indicators showed mixed signals, with both bearish and bullish trends observed.

The demand for Voyager Therapeutics' products and services is unlikely to exhibit typical consumer product seasonality. Demand is primarily driven by disease prevalence, clinical trial success, regulatory approvals, and market access, rather than seasonal fluctuations.

Voyager Therapeutics, Inc. is a biotechnology company focused on developing treatments and cures for severe neurological diseases by leveraging human genetics. The company's pipeline includes programs targeting Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis, and other central nervous system disorders, utilizing its TRACER™ adeno-associated virus capsid discovery platform. Key product candidates include VY7523, VY1706, SOD1 Silencing Gene Therapy, FXN Gene Therapy, ALPL-VYGR-NeuroShuttle, and a small molecule approach targeting TDP-43. Voyager collaborates with pharmaceutical companies and research organizations such as Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc.

Voyager Therapeutics is based in Cambridge, Massachusetts, with its corporate office in Lexington, MA. The company primarily operates in North America and Europe, focusing on regions with a high prevalence of neurological disorders. Voyager is actively exploring opportunities to expand into new geographic markets, particularly targeting Europe and Asia, with initiatives expected to commence within the next two years.

Voyager Therapeutics' reputation has been influenced by the challenges of advancing gene therapy programs for neurological diseases. Concerns have been raised regarding the viability of its pipeline and long-term profitability due to clinical trial setbacks and competition. Rising operational costs and dependence on external partnerships have also contributed to a negative perception. However, Voyager's innovative TRACER platform and promising preclinical results, along with its focus on blood-brain barrier delivery and the NeuroShuttle system, can positively impact its reputation.

Voyager Therapeutics has a mixed ownership structure. Approximately 42.13% of the company's stock is owned by institutional investors, with major shareholders including BlackRock, Inc., EcoR1 Capital, LLC, and Vanguard Group Inc. Public companies and individual investors own approximately 55.70% of the stock. Insiders hold about 2.17% of the company's stock, with top insider shareholders including Biosciences Inc Neurocrine and Capital, Llc Ecor1. Alfred Sandrock (President and CEO) led both buying and selling activity between December 2025 and March 2026.